Adults 18 to 75, any sex, with Non-segmental Vitiligo. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percent Change From Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24Primary· Baseline and Week 24
VASI is a validated scoring method that measures the extent and severity of vitiligo depigmentation. The F-VASI measures vitiligo involvement of the facial area. For facial lesions, size is estimated using fingertip units (FTU), fingers, or thumbs: 1 FTU is approximately 0.03% body surface area (BSA), while a finger or thumb is approximately 0.1% BSA. Depigmentation at each site is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. F-VASI is calculated by multiplying the area (in FTUs) by the depigmentation percentage for each facial site and summing the values. Scores ran
Group
Value
95% CI
MK-6194 3 mg Q2W
-4.55
-16.79 – 7.68
MK-6194 3 mg Q4W
-12.13
-24.29 – 0.03
Placebo
-4.01
-15.70 – 7.69
Number of Participants Who Experienced an Adverse Event (AE)Primary· Up to approximately 28 weeks
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who experienced an AE is reported.
Group
Value
95% CI
MK-6194 3 mg Q2W
51
MK-6194 3 mg Q4W
47
Placebo
44
Number of Participants Who Discontinued Study Treatment Due to an AEPrimary· Up to approximately 24 weeks
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.
Group
Value
95% CI
MK-6194 3 mg Q2W
9
MK-6194 3 mg Q4W
5
Placebo
1
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24Secondary· Baseline and Week 24
T-VASI is a validated scoring method that measures the extent and severity of vitiligo across the entire body. The body is divided into six regions: head/neck, hands, upper extremities, trunk, lower extremities, and feet. One hand unit (palm and fingers together) represents 1% of BSA. Depigmentation for each region is graded to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. For regions with multiple lesions, percentages are averaged. The T-VASI score is calculated by multiplying the area (in hand units) by the depigmentation percentage for each region and summing all regions. Sc
Group
Value
95% CI
MK-6194 3 mg Q2W
-1.69
-11.02 – 7.65
MK-6194 3 mg Q4W
-9.08
-18.24 – 0.08
Placebo
0.78
-7.77 – 9.34
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to approximately 61 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06821334 — A Single Dose Study of MK-6194 in Healthy Chinese Participants (MK-6194-014)
· Phase 1
· completed
NCT06161116 — Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
· Phase 2
· terminated
NCT06649877 — MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)
· Phase 1
· completed
NCT05450198 — Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
· Phase 1
· completed
NCT04924114 — A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
· Phase 1
· completed
Other recruiting trials for Non-segmental Vitiligo
Currently open trials in the same condition.
NCT07431177 — A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
· Phase 2
· recruiting
NCT07223229 — Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
· Phase 2
· recruiting
NCT07172347 — Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
· Phase 2
· recruiting
NCT07105254 — An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patien
· Phase 2
· recruiting
NCT06991972 — Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients
· Phase 4
· recruiting
Other Merck Sharp & Dohme LLC trials
Trials by the same sponsor.
NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005)
· Phase 2
· not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
· Phase 1, PHASE2
· recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527
· Phase 1
· not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M
· Phase 3
· not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06113328.